VIDEO: PCSK9 inhibitors cost-effective since price reductions

MIAMI — In this video, Jennifer G. Robinson, MD, discusses a statement prepared by the National Lipid Association and presented at their Scientific Sessions on the cost-effective treatment with PCSK9 inhibitors of patients with extremely high, very high and high risk for atherosclerotic CVD.

Robinson, professor and director of the Preventive Intervention Center at The University of Iowa College of Public Health in Iowa City, said that this statement serves as somewhat of an update to the 2018 multisociety cholesterol guideline since the PCSK9 inhibitor price reductions have gone into effect.

“This statement gives some guidance on who we should be targeting for PCSK9 monoclonal antibody therapy,” Robinson said.

Watch the video for more.